blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3085370

EP3085370 - CALEBIN A FOR INDUCING LIPOLYSIS [Right-click to bookmark this link]
Former [2016/43]CALEBIN A FOR HEPATIC STEATOSIS
[2018/31]
StatusNo opposition filed within time limit
Status updated on  02.08.2019
Database last updated on 14.09.2024
FormerThe patent has been granted
Status updated on  24.08.2018
FormerGrant of patent is intended
Status updated on  17.07.2018
FormerRequest for examination was made
Status updated on  21.04.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Majeed, Muhammed
117, Coppertree Court
Edison, NJ 08820 / US
For all designated states
Majeed, Anju
31 Matthew Court
Piscataway, NJ 08854 / US
For all designated states
Nagabhushanam, Kalyanam
39 Brooklawn Drive
East Windsor, NJ 08520 / US
[2016/43]
Inventor(s)01 / see applicant
...
 [2016/43]
Representative(s)Dr. Gassner & Partner mbB
Wetterkreuz 3
91058 Erlangen / DE
[N/P]
Former [2016/43]Dr. Gassner & Partner mbB
Marie-Curie-Str. 1
91052 Erlangen / DE
Application number, filing date15173299.723.06.2015
[2016/43]
Priority number, dateUS20151469043819.04.2015         Original published format: US201514690438
[2016/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3085370
Date:26.10.2016
Language:EN
[2016/43]
Type: B1 Patent specification 
No.:EP3085370
Date:26.09.2018
Language:EN
[2018/39]
Search report(s)(Supplementary) European search report - dispatched on:EP23.08.2016
ClassificationIPC:A61K31/216, A61P1/16, A61P3/04
[2016/43]
CPC:
A61K31/216 (EP); A61K31/215 (RU); A61P1/16 (EP);
A61P3/04 (EP); A61P3/06 (EP); A61P43/00 (EP);
A61K2121/00 (RU) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/21]
Former [2016/43]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:CALEBIN A UM LYPOLYSE ZU INDUZIEREN[2018/31]
English:CALEBIN A FOR INDUCING LIPOLYSIS[2018/31]
French:CALEBIN-A POUR INDUIRE LA LYPOLYSE[2018/31]
Former [2016/43]CALEBIN A ZUR LEBERSTEATOSE
Former [2016/43]CALEBIN A FOR HEPATIC STEATOSIS
Former [2016/43]CALEBIN-A POUR LA STÉATOSE HÉPATIQUE
Examination procedure23.06.2015Date on which the examining division has become responsible
18.04.2017Amendment by applicant (claims and/or description)
18.04.2017Examination requested  [2017/21]
18.07.2018Communication of intention to grant the patent
17.08.2018Fee for grant paid
17.08.2018Fee for publishing/printing paid
17.08.2018Receipt of the translation of the claim(s)
Opposition(s)27.06.2019No opposition filed within time limit [2019/36]
Fees paidRenewal fee
26.06.2017Renewal fee patent year 03
19.06.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.06.2015
AL26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
MK26.09.2018
MT26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
LU23.06.2019
[2022/31]
Former [2021/34]HU23.06.2015
AL26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
MT26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
LU23.06.2019
Former [2021/32]HU23.06.2015
AL26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
LU23.06.2019
Former [2021/26]AL26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
LU23.06.2019
Former [2020/27]AL26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
LU23.06.2019
Former [2020/08]AL26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/50]AL26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/34]AL26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/27]AL26.09.2018
CZ26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/24]AL26.09.2018
CZ26.09.2018
EE26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
SK26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/22]AL26.09.2018
CZ26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RO26.09.2018
RS26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/21]AL26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RS26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/20]AL26.09.2018
FI26.09.2018
HR26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RS26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/12]AL26.09.2018
FI26.09.2018
HR26.09.2018
LT26.09.2018
LV26.09.2018
RS26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/11]FI26.09.2018
HR26.09.2018
LT26.09.2018
RS26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/08]FI26.09.2018
LT26.09.2018
NO26.12.2018
Former [2019/07]LT26.09.2018
Documents cited:Search[X]WO2013109241  (MAJEED MUHAMMED [US], et al) [X] 2 * paragraphs [0008] , [0011] , [0019]; claims 1,4,8 *;
 [XY]US2014249219  (MAJEED MUHAMMED [US], et al) [X] 2 * paragraphs [0024] , [0025] * * example IV * * paragraph [0110]; tables VI,X * * claims 1-5,8,9 * [Y] 1;
 [E]EP2937084  (MAJEED MUHAMMED [US], et al) [E] 1 * paragraph [0025]; claims 9-11; table IV *;
 [Y]  - RAMIN KAFFASHI ELAHI, "Preventive effects of Turmeric (Curcuma longa Linn.) Powder on hepatic steatosis in the rats fed with high fat diet", LIFE SCIENCE JOURNAL, (20120101), vol. 9, no. 4, pages 5462 - 5468, XP055295414 [Y] 1 * the whole document *
 [T]  - CHING-SHU LAI ET AL, "Calebin-A inhibits adipogenesis and hepatic steatosis in high-fat diet-induced obesity via activation of AMPK signaling", MOLECULAR NUTRITION & FOOD RESEARCH, DE, (20150720), vol. 59, no. 10, doi:10.1002/mnfr.201400809, ISSN 1613-4125, pages 1883 - 1895, XP055295127 [T] * the whole document *

DOI:   http://dx.doi.org/10.1002/mnfr.201400809
Examination   - BAYS HAROLD E ET AL, "Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.", EXPERT REVIEW OF CARDIOVASCULAR THERAPY MAR 2008, (200803), vol. 6, no. 3, ISSN 1744-8344, pages 343 - 368
    - GUSTAFSON BIRGIT ET AL, "Insulin resistance and impaired adipogenesis.", TRENDS IN ENDOCRINOLOGY AND METABOLISM: TEM APR 2015, (201504), vol. 26, no. 4, ISSN 1879-3061, pages 193 - 200
by applicant   - PARK S Y ET AL., J NAT PROD., (200209), vol. 65, no. 9, pages 1227 - 31
    - LI Y ET AL., EUR J. PHARMACOL., (20080904), vol. 591, no. 1-3, pages 252 - 8
    - ZENG Y ET AL., CHEM PHARM BULL (TOKYO, (200706), vol. 55, no. 6, pages 940 - 3
    - WU Z; XIE Y; MORRISON R F; BUCHER NLR; FARMER SR, "PPAR y induces the Insulin-dependent Glucose Transporter GLUT4 in the absence of C/EBPo during the conversion of 3T3 fibroblasts into adipocytes", J CLIN INVEST., (1998), vol. 101, pages 22 - 32
    - L A SALAZAR-OLIVO; F CASTRO-MUNOZLEDO; W KURI-HARCUCH, "A pre-adipose 3T3 cell variant highly sensitive to adipogenic factors & to human growth hormone", JOURNAL OF CELL SCIENCE, (1995), vol. 108, no. 5, pages 2101 - 2107
    - MINGUI FU; TINGWAN SUN; ANGIE L. BOOKOUT; MICHEAL DOWNES; RUTH T. YU; RONALD M. EVANS; DAVID J. MANGELSDORF., "A Nuclear Receptor Atlas: 3T3-L1 Adipogenesis", MOLECULAR ENDOCRINOLOGY, (2005), vol. 19, no. 10, pages 2437 - 2450
    - AIMEE D KOHN ET AL., "Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation", J. BIOL. CHEM., (1996), vol. 271, doi:doi:10.1074/jbc.271.49.31372, pages 31372 - 31378, XP002558471

DOI:   http://dx.doi.org/10.1074/jbc.271.49.31372
    - TAMAR. R., "Aprahamian and Flora Sam, ''Adiponectin in Cardiovascular Inflammation and Obesity", INT J. INFLAM., (2011), page 376909
    - HOTTA K; FUNAHASHI T; ARITA Y ET AL., "Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis", THROMBOSIS AND VASCULAR BIOLOGY, (2000), vol. 20, no. 6, pages 1595 - 1599, XP002952714
    - IWASHIMA Y; KATSUYA T; ISHIKAWA K ET AL., "Hypoadiponectinemia is an independent risk factor for hypertension", HYPERTENSION, (2004), vol. 43, no. 6, pages 1318 - 1323
    - KUMADA M; KIHARA S; SUMITSUJI S ET AL., "Association of hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis", THROMBOSIS AND VASCULAR BIOLOGY, (2003), vol. 23, no. 1, pages 85 - 89
    - LINDSAY R S; FUNAHASHI T; HANSON R L ET AL., "Adiponectin and development of type 2 diabetes in the Pima Indian population", THE LANCET, (2002), vol. 360, no. 9326, doi:doi:10.1016/S0140-6736(02)09335-2, pages 57 - 58, XP004790509

DOI:   http://dx.doi.org/10.1016/S0140-6736(02)09335-2
    - BASTARD JP ET AL., "Recent Advances in the relationship between obesity, inflammation and insulin resistance", EUR CYTOKINE NETW., (200603), vol. 17, no. 1, pages 4 - 12
    - CLARA, B.; R. C. ARANCHA; G. M. ANDRE'S; P. ATANASIO; A. JULIA; O. ALBERTO, "A new method for detecting TNF-a-secreting cells using direct immunofluorescence surface membrane stainings", J. IMMUNO. METHODS, (2003), vol. 264, doi:doi:10.1016/S0022-1759(02)00083-2, pages 77 - 87, XP004362071

DOI:   http://dx.doi.org/10.1016/S0022-1759(02)00083-2
    - KHURSHID A. BHAT; BHAHWAL A. SHAH; KULDEEP K. GUPTA; ANJALI PANDEY; SARANG BANI; SUBHASH C., "Taneja. Semi-synthetic analogs of pinitol as potential inhibitors of TNF-a cytokine expression in human neutrophils", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2009), vol. 19, doi:doi:10.1016/j.bmcl.2009.02.050, pages 1939 - 1943, XP025974894

DOI:   http://dx.doi.org/10.1016/j.bmcl.2009.02.050
    - BRIEVA A; GUER-RERO A; ALONSO-LEBRERO J L; PIVEL J P., "Immunoferon, a glycoconjugate of natural origin, inhibits LPS-induced TNF-a production and inflammatory responses", INTERNATIONAL LMMUNOPHARMACOLOGY, (2001), vol. 1, pages 1979 - 1987
    - BEHNKE, A. R., "Lean body mass", A.M.A. ARCH. INT. MED., (1953), vol. 91, page 585
    - H.F.KRAYBILL ET AL., J ANIM SCI, (1954), vol. 13, pages 548 - 555
    - CHAMUKUTTAN SNEHALATHA ET AL., "Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians", DIABETES CARE, (200312), vol. 26, no. 12, doi:doi:10.2337/diacare.26.12.3226, pages 3226 - 3229, XP055423536

DOI:   http://dx.doi.org/10.2337/diacare.26.12.3226
    - KLEINER, D.E.; BRUNT, E.M.; VAN, N.M.; BEHLING, C. ET AL., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", HEPATOLOGY, (2005), vol. 41, doi:doi:10.1002/hep.20701, pages 1313 - 1321, XP055123202

DOI:   http://dx.doi.org/10.1002/hep.20701
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.